Compare
Larimar Therapeutics, Inc. vs XBiotech Inc. vs Prelude Therapeutics Inc vs Whitehawk Therapeutics, Inc.
| Latest fiscal year | Larimar Therapeutics, Inc. LRMR | XBiotech Inc. XBIT | Prelude Therapeutics Inc PRLD | Whitehawk Therapeutics, Inc. WHWK |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $12.14M | $7.14M |
| Revenue growth (YoY) | n/a | n/a | +73.4% | -72.5% |
| Gross margin | n/a | n/a | n/a | 89.4% (computed) |
| Operating margin | n/a | n/a | -861.3% | n/m |
| Net margin | n/a | n/a | -819.6% | -288.3% |
| Net income | -$165.67M | -$45.54M | -$99.50M | -$20.60M |
| EPS (Diluted) | n/a | -$1.49 | -$1.29 | -$0.33 |
| Operating cash flow | -$113.20M | -$39.92M | -$56.30M | -$97.43M |
| Free cash flow | -$113.29M | -$40.21M | -$56.37M | -$97.98M |
| Cash & equivalents | $85.41M | $125.55M | $35.26M | $37.57M |
| Total assets | $145.84M | $150.08M | $141.31M | $150.83M |
| Total liabilities | $67.76M | $9.73M | $72.68M | $14.52M |
| Shareholders' equity | $78.08M | $140.35M | $68.64M | $136.31M |
| Return on year-end equity | -212.2% | -32.4% | -145.0% | -15.1% |
| Shares outstanding | 83.09M | 30.49M | n/a | 47.15M |
Revenue, most recent five fiscal years
| Fiscal year | Larimar Therapeutics, Inc. | XBiotech Inc. | Prelude Therapeutics Inc | Whitehawk Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2019-12-31 | $0 Ended 2023-12-31 | $12.14M Ended 2025-12-31 | $7.14M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2018-12-31 | $4.01M Ended 2022-12-31 | $7.00M Ended 2024-12-31 | $25.98M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2017-12-31 | $18.39M Ended 2021-12-31 | n/a | $24.35M Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2016-12-31 | $44.00M Ended 2020-12-31 | n/a | $15.22M Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2015-12-31 | $0 Ended 2019-12-31 | n/a | $14.00M Ended 2021-12-31 |